Kornimate/medical-research-clean huggingface dataset:
the gastric hormone biomarkers of preneoplastic lesions study

Conditions: Stomach Neoplasm; Chronic Atrophic Gastritis; Intestinal Metaplasia

Summary: the goal of the study is to understand whether blood levels of hormones produced or metabolized in the stomach reflect the health of the stomach lining. specifically the study will determine whether the concentration of ghrelin, gastrin, pepsinogens and vitamin b12 reflect the condition of the stomach lining. hormone concentrations for people with normal/mild gastritis will be compared to people with long-term inflammation of the stomach (chronic atrophic gastritis), and people with pre-cancerous cellular changes (intestinal metaplasia).

previously published promising data show that blood levels of ghrelin, gastrin, vitamin b12 and pepsinogen are each associated with risk of developing stomach cancer. these studies used blood bank samples and looked at risk of cancer many decades later. this study was designed to explore whether these markers could be useful in a clinical setting for early detection of stomach cancer. the study will recruit at 3 sites over 1 year identifying patients with chronic atrophic gastritis and intestinal metaplasia and those with mild gastritis. only the patient data which is absolutely necessary for analysis will be collected, to include basic demographics, relevant medical history and medications. these data will be used to analytically account for alternative explanations for variation in blood measurements of ghrelin, gastrin, pepsinogen and vitamin b12. a one-time venous blood sample will be collected to enable measurement of the markers of interest.

Eligibility criteria:
inclusion criteria: 1. adult patients (18-80 years old) attending upper gastrointestinal endoscopy. 2. patients able to read and comprehend english. 3. patients willing and able to provide informed consent. 4. patients willing and able to provide a venous blood sample. exclusion criteria: 1. any individual diagnosed with gastric cancer, or with a history of gastric cancer, prior gastrectomy or bariatric surgery. 2. any individual with a chronic inflammatory condition of the gastrointestinal tract (crohn's disease or ulcerative colitis). 3. once enrolment ceiling is reached for each group, enrolment will close for that group. the study will continue until all groups are complete.
a randomized controlled trial comparing the efficacy of commercial weight management programs

Conditions: Obesity and Overweight

Summary: the study compares the effectiveness of three commercial weight management programs. the primary outcome is absolute and percentage weight change at 12-weeks.


Eligibility criteria:
inclusion criteria: * 18 years or older * bmi ≥27 kg/m² * own a bodyweight scale that they can weigh themselves with during the study * willing and able to comply with study protocol * capable of providing informed consent * able to read and write in english * willing to be randomized * willing to sign a non disclosure agreement exclusion criteria: * pregnant, lactating, or plans to become pregnant in the next 6 months * previous bariatric surgery or planned bariatric surgery during the study period * major surgery within the past 6 months or plans to have surgery during the study period * participation in the previous 3 months or current participation in a structured behavioral weight loss program * participation in another structured weight loss program during the study period (i.e., the next 3 months) * communication needs that would render them unable to understand the study and/or intervention materials * current or previous history of anorexia or bulimia nervosa * engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight * currently taking anti-obesity medications, planning to take anti-obesity medications in the next 6 months, or previously taken anti-obesity medications in the previous 3 months * weight loss of ≥ 5 kg (11 lb) in the previous 6 months * self-reported diagnosis of severe depression, bipolar disorder, substance abuse, or psychosis * participants who are involved in any other research studies at this time * untreated thyroid disease or any changes (type or dose) in thyroid medication in last 6 months * chronic/inflammatory gastrointestinal disorders (irritable bowel syndrome is acceptable) * history of heart problems (e.g., angina, bypass surgery, myocardial infarction, etc.) within previous 6 months * diagnosis of type 1 or type 2 diabetes * presence of implanted cardiac defibrillator or pacemaker * history of cancer within past 5 years or current treatment for cancer * hospitalization for psychiatric disorders during the last 12 months
physical therapy prior to total knee replacement

Conditions: Osteoarthritis of the Hip

Summary: in this study, the investigators are investigating the effects of physical therapy (pt) for treating high grade knee osteoarthritis (oa) in patients that are candidates for total knee replacement. through the examination of patient outcomes, such as pain, stiffness, and physical function, the investigators will determine if pt prior to total knee replacement is an effective treatment in a patient with high grade oa.


Eligibility criteria:
inclusion criteria: 1. knee osteoarthritis (kellgren-lawrence grade 3 or 4) confirmed via standing ap radiograph 2. surgical candidate for tka, having had a least a 3 months of pain affecting adl's unresponsive to conservative treatment consisting of at least one non-narcotic medication and one injection (corticosteroid or series of viscosupplementation). injection must not have been administered within 6 weeks of start of pt trial 3. prior knee surgery from arthroscopies, meniscal surgery and ligament reconstruction exclusion criteria: 1. anyone who received physical therapy in the last 6 months 2. inability to walk unaided for \>1 block 3. currently engaged in regular pt or a regular home exercise program 4. prior knee arthroplasty 5. prior knee surgery for trauma, tumor and osteotomy 6. injection given within 6 weeks of starting therapy 7. patients using daily narcotic medications within prior 6 weeks
quantitative diffusion and fat imaging of the spine

Conditions: Osteoporosis

Summary: primary objective: the purpose of this study is to determine whether or not combined quantitative diffusion and fat mr imaging techniques can differentiate between benign and malignant vertebral fractures.

researchers believe that they may be able to use mri scans to tell if fractures of the bones in the spine are due to cancer. they believe this can be done by looking at mris of diffusion (the random motion of molecules) and fat. for benign and malignant processes, either diffusion or fat, or both of them, can be different, because the cell density (which affects diffusion) and bone marrow content (which affects fat) are expected to be different. all patients in this study will have already been scheduled for mri exams of the spine at utmdacc. you will have one extra mri sequence done to look for relative fat, and a second extra mri sequence done to look for the diffusion. the extra time required for the study should be less than 10 minutes, and the total imaging time should fall within a standard mri time slot. available data from your medical record, including imaging data, will be used to set up guidelines and clear examples for checking spinal fractures. this is an investigational study. a total of 48 patients will take part in the study. all will be enrolled at utmdacc.

Eligibility criteria:
inclusion criteria: 1. patients with suspected vertebral compression fractures scheduled a standard of care mri of the spine. exclusion criteria: 1. patients who are contraindicated for mri (such as due to metal implants, cardiac pacemaker). 2. patients who are unable to give informed consent 3. patients who are younger than 18 years of age since the disease (osteoporosis) is not present in children.

Keywords: osteoporosis magnetic resonance imaging vertebral fractures quantitative diffusion fat imaging spine
open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (cll)

Conditions: Chronic Lymphocytic Leukemia

Summary: open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (cll).

this is an open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (cll).

Eligibility criteria:
inclusion criteria: * the subject has been dosing in arm c of the abt4710n study, has not discontinued for any reason prior to study closure and the investigator believes that continued treatment with navitoclax is in the best interest of the subject * the subject must meet defined hematology and coagulation lab criteria as specified in the protocol * the subject must meet defined chemistry criteria as specified in the protocol * women of childbearing potential and men must agree to use adequate contraception (as per protocol) prior to study entry, for the duration of study participation and up to 90 days following completion of therapy * the subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign the informed consent form exclusion criteria: * the subject discontinued navitoclax administration in arm c of the abt4710n study for reasons of disease progression, adverse event toxicity, withdrawal of consent or investigator decision prior to study completion. * the subject has any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities. * the subject is a lactating or pregnant female.
sepsis in oncology patients

Conditions: Sepsis in Cancer Patients

Summary: the overall objective of this prospective observational study is to address the significant knowledge gap that exists around the impact of immune dysfunction on the development and survival from sepsis in patients with cancer. this proposal primarily focuses on establishing the transcriptomic immune profiles of sepsis patients with a background of cancer. this analysis will be complemented with in vitro functional analyses, and in addition will commence a collection of genome-wide data, including a focus on predicting white cell number and function in health. uniquely, the investigators propose to establish a robust link between these analyses: transcriptomic, in vitro, and genome-wide, to enable them to comprehensively explore septic oncology patient 'immune phenotypes' and effectively identify novel exploitable therapeutic pathways. to this end, this project will collect, analyse and/or sequence dna, rna, leukocytes and soluble materials from a cohort of oncology patients presenting to intensive care with sepsis. this cohort will include all-comers with an oncological background but will also focus on two core groups at high risk of sepsis where baseline samples can also be sought prior to major immunosuppressive events in the cancer pathway. these are: 1. oesophageal/upper gastrointestinal (gi) cancer patients prior to systemic anticancer therapy initiation or surgery 2. haematological malignancy patients prior to stem cell transplantation. these sub-cohorts will provide a previously unexplored unique insight into the role of pre-existing patient transcriptomic phenotypes.

the specific aims will be to perform multi-modal parallel immune phenotyping to determine: * the transcriptomic (rna) phenotypes (or 'signatures') of cancer patients with sepsis * the association of these transcriptomic phenotypes with: 1. leukocyte function in sepsis, as quantified by cell surface and functional assays and plasma soluble mediator content 2. pre-existing genomic determinants such as leukocyte numbers 3. severity of, and outcome from, sepsis in oncology patients

Eligibility criteria:
sepsis cohort: inclusion criteria: * patients admitted to icu with a diagnosis of sepsis as per 'sepsis-3' definitions with a sofa score \[ref\] ≥2 secondary to infection from any source * ≥18 years of age * written consent from patient, personal or professional consultee, or deferred consent if none of the above available at admission sepsis cohort exclusion criteria: • death deemed imminent by the clinical team elective cohort inclusion criteria * patients undergoing elective major upper gi surgery (oesophago+/-gastrectomy) or stem cell transplant for haematological malignancy * ≥18 years of age * written consent from patient elective cohort exclusion criteria • limitations in place regarding provision of treatment and/or organ support e.g., palliative patients
preclinical validation of new anti-melanoma compounds

Conditions: Melanoma

Summary: this research program is in keeping with the chemistry/biology/clinical interface and gathers 4 teams with complementary expertise in these respective fields. it will allow deciphering the mechanism(s) of action of new thiazole-benzenesulfonamide family (tzb) derivatives on metastatic melanoma sensitive and resistant to braf and mek inhibitors. investigators will use melanoma cell lines and primary cells from patients to validate these compounds in collaboration with clinical team 2 and 4. in conclusion, the investigators expect to establish the proof of concept that this new class of bioactive molecules (first in class) we developed in collaboration with team 3 have the potential to go to the clinic for the treatment of highly aggressive cancers and particularly metastatic melanoma sensitive and resistant b-raf and mek inhibitors. furthermore, the realization of this project can undoubtedly increase the knowledge of mechanisms and signaling pathways that are involved in resistant to braf and mek inhibitors, and allow the selection of drug candidates capable of restoring the sensitivity of these melanoma cells.


Eligibility criteria:
inclusion criteria: * patient with metastatic melanoma * not opposition of the patient will have been looked for exclusion criteria: * primary resistance, * absence of resistance, * patient already included in other trials

Keywords: skin metastasis resistance endoplasmic reticulum stress metastasis
clinical assessment method in patients using non-invasive ventilation

Conditions: Respiratory Failure

Summary: this is an observational study of recording the respiratory parameters of patients when receiving non-invasive ventilation and analyze the relationship between those parameters and clinical outcomes.

non-invasive positive pressure ventilation (nppv) is undoubtedly one of the most important advances in mechanical ventilation technology in the past 30 years. currently, nppv has become an essential respiratory support technology in hospitals, and it is used in different fields, including respiratory and critical care, emergency care, anesthesia, and rehabilitation. applications of nppv are also gradually expanding from intensive care units (icus) and respiratory wards to use in other medical departments and at home. this is an observational study of recording the respiratory parameters of patients when receiving non-invasive ventilation and analyze the relationship between those parameters and clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. age 18-80, males and females 2. patients with hypercapnic respiratory failure 3. willing to participate in the study. 4. being able to provide informed consent. exclusion criteria: 1. subjects with severe heart failure, severe arrhythmias, unstable angina, and malignant comorbidities. 2. subjects with significantly impaired cognitive function and are unable to fulfill the study requirement (unable to provide informed consent) 3. subjects who participated in another trial within 30 days prior to the planned start of the study
impact of new clsi guidelines on antibiotic susceptability pattern

Conditions: Antibiotic Susceptibility Patterns

Summary: assessing the precise mic for the ceftriaxone using e-test. to determine what proportion of susceptibility reports will be reclassified based on the new clsi guidelines.antibiotic susceptibility reports of blood cultures, urine cultures,aseptic body fluid cultures growing enterobacteriaceae organism generated by the phoenix machine will be obtained on a daily basis.mic for ceftriaxone will be noted.if the mic is \<=2 for ceftriaxone,those cultures would be used to run an additional test - e- test.e-test gives us more precise mic values compared to phoenix machine.we will analyze the data collected over 2 months. we will determine the proportion of susceptibility reports reclassified based on the new clsi guidelines.


Eligibility criteria:
inclusion criteria: * antibiotic susceptibility reports of blood cultures, urine cultures,aseptic body fluid cultures growing enterobacteriaceae organism generated by the phoenix machine. exclusion criteria: * none
administration of cbg000592 (riboflavin/vitamin b2) in patients with acute ischemic stroke

Conditions: Ischemic Stroke

Summary: administration of cbg000592 (riboflavin/vitamin b2) in patients with acute ischemic stroke to know if it causes a reduction of glutamate-mediated excitotoxicity.

the investigators hypothesis focuses on the effect of riboflavin given for the first three hours of ischemic stroke, as a reducing agent of cerebral glutamate concentration. this administration would produce a reduction of excitotoxic damage and consequently generate clinical improvement, while a lower income and a better functional outcome of patients at three months.

Eligibility criteria:
inclusion criteria: 1. patients older than 18 years, both men and women. 2. patient or legal representative able to understand and sign the informed consent. 3. patients with suspected stroke within 3 hours of onset. exclusion criteria: 1. women of childbearing age, with potential for pregnancy or breastfeeding. 2. patients with a score ≥ 2 point 1a in the nihss scale. 3. scale pre-stroke modified rankin ≥ 2. 4. inability to prior testing image needed for the study. 5. previous disorders that may interfere with the interpretation of neurological scales. 6. treatment with probenecid, tricyclic antidepressants, phenothiazines, streptomycin, erythromycin, tyrothricin, tetracyclines and carbomycin, at the time of inclusion.

Keywords: ischemic stroke vitamin b2
causes, characteristics and treatment of hypercalcemia in the emergency room of a german hospital

Conditions: Hypercalcemia

Summary: patients with hypercalcemia were identified in the patient population of a german emergency department during a 11 year time period and studied regarding reproducibility of elevated calcium values, causes of hypercalcemia, symptoms. acute renal injury, mortality and treatment response.

patients, who presented to the emergency department of a tertiary german hospital with a total calcium of ≥2.65 mmol/l between january 2010 and march 2021, was retrospectively studied. from the electronic patient records we analyzed if the elevated calcium values were reproducible in follow-up measurements, identified the cause of hypercalcemia, listed the symptoms, investigated a correlation between calcium and creatinine values to study acute renal injury directly due to hypercalcemia, calculated the mortality rate stratified by the calcium value on presentation and studied the treatment response regarding lowering calcium values by different treatments.

Eligibility criteria:
inclusion criteria: * age \> 18 years * total calcium ≥ 2.65 mmol/l * female and male exclusion criteria: * age \< 18 years * total calcium \< 2.65 mmol/

Keywords: hypercalcemia calcium emergency room mortality
surrogate of adequate perfusion: bladder tissue oxygen monitoring

Conditions: Shock; Sepsis; Surgery

Summary: the extent and duration of tissue hypoxia is a major determinant of outcome following major, high-risk surgery and in critical illness. prompt restoration of tissue oxygenation through resuscitation in all likelihood improves outcomes. there are currently no bedside monitors in clinical practice that track tissue perfusion per se, instead clinicians rely on crude surrogates such as heart rate and blood pressure, urine output, serum lactate of global flow (cardiac output) monitoring. this is a first-in-man trial of a new device to measure tissue oxygenation in real time in a major, high-risk surgical and critical care cohort. the device consists of an oxygen sensing probe incorporated into a modified urinary catheter, which relies on photoluminescence technology and the quenching properties of oxygen. once inserted, the drained bladder collapses round and envelopes the probe which continuously measures tissue oxygenation of the bladder urothelium. the investigators hope to (i) establish that tissue oxygenation can be safely monitored using this technology, deployed in this way. (ii) define a normal range for bladder tissue oxygenation in man as measured using this device. (iii) compare tissue oxygenation against other markers of perfusion status in current clinical practice and assess its performance at detecting inadequate perfusion against these other modalities. (iv) assess the diagnostic and prognostic capabilities of the tissue oxygenation monitoring at detecting hypo-perfusion and predicting outcome. (v) further assess the tissue response to an 'oxygen challenge' in identifying occult hypo-perfusion. (vi). provide pilot work required to inform future, interventional studies where similar patients would be resuscitated to tissue oxygenation targets alongside routine clinical practice.

as above

Eligibility criteria:
inclusion criteria: * having major elective or emergency surgery (deemed to need invasive bp monitoring by anaesthetist) and a urinary catheter * or emergency admission to critical care (necessitating arterial line and urinary catheter). exclusion criteria: * age \<18 * pregnancy * contraindication to arterial cannulation or urethral catheterisation * surgery on lower urinary tract/bladder * patient refusal